1
|
Laus AC, Gomes INF, da Silva ALV, da Silva LS, Milan MB, AparecidaTeixeira S, Martin ACBM, do Nascimento Braga Pereira L, de Carvalho CEB, Crovador CS, de Paula FE, Nascimento FC, de Freitas HT, de Lima Vazquez V, Reis RM, da Silva-Oliveira RJ. Establishment and molecular characterization of HCB-541, a novel and aggressive human cutaneous squamous cell carcinoma cell line. Hum Cell 2024; 37:1170-1183. [PMID: 38565739 PMCID: PMC11194207 DOI: 10.1007/s13577-024-01054-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2023] [Accepted: 03/04/2024] [Indexed: 04/04/2024]
Abstract
Cutaneous squamous cell carcinoma (cSCC) is a common type of skin cancer that can result in significant morbidity, although it is usually well-managed and rarely metastasizes. However, the lack of commercially available cSCC cell lines hinders our understanding of this disease. This study aims to establish and characterize a new metastatic cSCC cell line derived from a Brazilian patient. A tumor biopsy was taken from a metastatic cSCC patient, immortalized, and named HCB-541 after several passages. The cytokeratin expression profile, karyotypic alterations, mutational analysis, mRNA and protein differential expression, tumorigenic capacity in xenograft models, and drug sensitivity were analyzed. The HCB-541 cell line showed a doubling time between 20 and 30 h and high tumorigenic capacity in the xenograft mouse model. The HCB-541 cell line showed hypodiploid and hypotetraploidy populations. We found pathogenic mutations in TP53 p.(Arg248Leu), HRAS (Gln61His) and TERT promoter (C228T) and high-level microsatellite instability (MSI-H) in both tumor and cell line. We observed 37 cancer-related genes differentially expressed when compared with HACAT control cells. The HCB-541 cells exhibited high phosphorylated levels of EGFR, AXL, Tie, FGFR, and ROR2, and high sensitivity to cisplatin, carboplatin, and EGFR inhibitors. Our study successfully established HCB-541, a new cSCC cell line that could be useful as a valuable biological model for understanding the biology and therapy of metastatic skin cancer.
Collapse
Affiliation(s)
- Ana Carolina Laus
- Molecular Oncology Research Center, Barretos Cancer Hospital, Antenor Duarte Villela, 1331, Barretos, São Paulo, Zip Code: 14784 400, Brazil
| | - Izabela Natalia Faria Gomes
- Molecular Oncology Research Center, Barretos Cancer Hospital, Antenor Duarte Villela, 1331, Barretos, São Paulo, Zip Code: 14784 400, Brazil
| | - Aline Larissa Virginio da Silva
- Molecular Oncology Research Center, Barretos Cancer Hospital, Antenor Duarte Villela, 1331, Barretos, São Paulo, Zip Code: 14784 400, Brazil
| | - Luciane Sussuchi da Silva
- Molecular Oncology Research Center, Barretos Cancer Hospital, Antenor Duarte Villela, 1331, Barretos, São Paulo, Zip Code: 14784 400, Brazil
| | - Mirella Baroni Milan
- Molecular Oncology Research Center, Barretos Cancer Hospital, Antenor Duarte Villela, 1331, Barretos, São Paulo, Zip Code: 14784 400, Brazil
| | - Silvia AparecidaTeixeira
- Molecular Oncology Research Center, Barretos Cancer Hospital, Antenor Duarte Villela, 1331, Barretos, São Paulo, Zip Code: 14784 400, Brazil
| | - Ana Carolina Baptista Moreno Martin
- Molecular Oncology Research Center, Barretos Cancer Hospital, Antenor Duarte Villela, 1331, Barretos, São Paulo, Zip Code: 14784 400, Brazil
| | - Letícia do Nascimento Braga Pereira
- Molecular Oncology Research Center, Barretos Cancer Hospital, Antenor Duarte Villela, 1331, Barretos, São Paulo, Zip Code: 14784 400, Brazil
| | | | - Camila Souza Crovador
- Department of Surgery of Melanoma and Sarcoma, Barretos Cancer Hospital, São Paulo, Brazil
| | - Flávia Escremin de Paula
- Molecular Oncology Research Center, Barretos Cancer Hospital, Antenor Duarte Villela, 1331, Barretos, São Paulo, Zip Code: 14784 400, Brazil
| | - Flávia Caroline Nascimento
- Molecular Oncology Research Center, Barretos Cancer Hospital, Antenor Duarte Villela, 1331, Barretos, São Paulo, Zip Code: 14784 400, Brazil
| | - Helder Teixeira de Freitas
- Molecular Oncology Research Center, Barretos Cancer Hospital, Antenor Duarte Villela, 1331, Barretos, São Paulo, Zip Code: 14784 400, Brazil
| | - Vinicius de Lima Vazquez
- Molecular Oncology Research Center, Barretos Cancer Hospital, Antenor Duarte Villela, 1331, Barretos, São Paulo, Zip Code: 14784 400, Brazil
- Department of Surgery of Melanoma and Sarcoma, Barretos Cancer Hospital, São Paulo, Brazil
| | - Rui Manuel Reis
- Molecular Oncology Research Center, Barretos Cancer Hospital, Antenor Duarte Villela, 1331, Barretos, São Paulo, Zip Code: 14784 400, Brazil
- Life and Health Sciences Research Institute (ICVS) Medical School, University of Minho, Braga, Portugal
- ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Portugal
- Barretos School of Health Sciences, Dr. Paulo Prata-FACISB, Barretos, São Paulo, Brazil
| | - Renato José da Silva-Oliveira
- Molecular Oncology Research Center, Barretos Cancer Hospital, Antenor Duarte Villela, 1331, Barretos, São Paulo, Zip Code: 14784 400, Brazil.
- Barretos School of Health Sciences, Dr. Paulo Prata-FACISB, Barretos, São Paulo, Brazil.
| |
Collapse
|
2
|
Ugwu DI, Conradie J. Anticancer properties of complexes derived from bidentate ligands. J Inorg Biochem 2023; 246:112268. [PMID: 37301166 DOI: 10.1016/j.jinorgbio.2023.112268] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2023] [Revised: 05/09/2023] [Accepted: 05/27/2023] [Indexed: 06/12/2023]
Abstract
Cancer is the abnormal division and multiplication of cells in an organ or tissue. It is the second leading cause of death globally. There are various types of cancer such as prostate, breast, colon, lung, stomach, liver, skin, and many others depending on the tissue or organ where the abnormal growth originates. Despite the huge investment in the development of anticancer agents, the transition of research to medications that improve substantially the treatment of cancer is less than 10%. Cisplatin and its analogs are ubiquitous metal-based anticancer agents notable for the treatment of various cancerous cells and tumors but unfortunately accompanied by large toxicities due to low selectivity between cancerous and normal cells. The improved toxicity profile of cisplatin analogs bearing bidentate ligands has motivated the synthesis of vast metal complexes of bidentate ligands. Complexes derived from bidentate ligands such as β-diketones, diolefins, benzimidazoles and dithiocarbamates have been reported to possess 20 to 15,600-fold better anticancer activity, when tested on cell lines, than some known antitumor drugs currently on the market, e.g. cisplatin, oxaliplatin, carboplatin, doxorubicin, and 5-fluorouracil. This work discusses the anticancer properties of various metal complexes derived from bidentate ligands, for possible application in chemotherapy. The results discussed were evaluated by the IC50 values as obtained from cell line tests on various metal-bidentate complexes. The structure-activity relationship study of the complexes discussed, revealed that hydrophobicity is a key factor that influences anticancer properties of molecules.
Collapse
Affiliation(s)
- David Izuchukwu Ugwu
- Department of Chemistry, University of the Free State, South Africa; Department of Pure and Industrial Chemistry, University of Nigeria, Nsukka, Nigeria
| | - Jeanet Conradie
- Department of Chemistry, University of the Free State, South Africa.
| |
Collapse
|
3
|
The Barretos Cancer Hospital Animal Facility: Implementation and Results of a Dedicated Platform for Preclinical Oncology Models. Vet Sci 2022; 9:vetsci9110636. [DOI: 10.3390/vetsci9110636] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2022] [Revised: 10/11/2022] [Accepted: 10/17/2022] [Indexed: 11/19/2022] Open
Abstract
The Barretos Cancer Hospital Animal Facility (BCHAF) is a unique facility in Brazil exclusively dedicated to working with animal models for cancer research. In this article, we briefly present our modern facility and the main experiments performed, focusing on mutant strains of mice (PTCH-knockout and ApcMin mice), xenograft models, and patient-derived xenografts (PDXs). Our results show the progress and challenges in establishing these models and the need for having an appropriate representation of our cancer population to better understand tumor biology and to identify cancer biomarkers, which could be putatively targeted, allowing for personalized therapy.
Collapse
|
4
|
da Silva J, da Costa CC, de Farias Ramos I, Laus AC, Sussuchi L, Reis RM, Khayat AS, Cavalli LR, Pereira SR. Upregulated miRNAs on the TP53 and RB1 Binding Seedless Regions in High-Risk HPV-Associated Penile Cancer. Front Genet 2022; 13:875939. [PMID: 35812732 PMCID: PMC9263206 DOI: 10.3389/fgene.2022.875939] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2022] [Accepted: 05/26/2022] [Indexed: 12/13/2022] Open
Abstract
Cancer development by the human papillomavirus (HPV) infection can occur through the canonical HPV/p53/RB1 pathway mediated by the E2/E6/E7 viral oncoproteins. During the transformation process, HPV inserts its genetic material into host Integration Sites (IS), affecting coding genes and miRNAs. In penile cancer (PeCa) there is limited data on the miRNAs that regulate mRNA targets associated with HPV, such as the TP53 and RB1 genes. Considering the high frequency of HPV infection in PeCa patients in Northeast Brazil, global miRNA expression profiling was performed in high-risk HPV-associated PeCa that presented with TP53 and RB1 mRNA downregulated expression. The miRNA expression profile of 22 PeCa tissue samples and five non-tumor penile tissues showed 507 differentially expressed miRNAs: 494 downregulated and 13 upregulated (let-7a-5p, miR-130a-3p, miR-142-3p, miR-15b-5p miR-16-5p, miR-200c-3p, miR-205-5p, miR-21-5p, miR-223-3p, miR-22-3p, miR-25-3p, miR-31-5p and miR-93-5p), of which 11 were identified to be in HPV16-IS and targeting TP53 and RB1 genes. One hundred and thirty-one and 490 miRNA binding sites were observed for TP53 and RB1, respectively, most of which were in seedless regions. These findings suggest that up-regulation of miRNA expression can directly repress TP53 and RB1 expression by their binding sites in the non-canonical seedless regions.
Collapse
Affiliation(s)
- Jenilson da Silva
- Postgraduate Program in Health Science, Federal University of Maranhão, São Luís, Brazil
| | - Carla Cutrim da Costa
- Degree in Biological Sciences, Department of Biology, Federal University of Maranhão, São Luís, Brazil
| | - Ingryd de Farias Ramos
- Postgraduate Program in Oncology and Medical Sciences, Federal University of Pará, Belém, Brazil
| | - Ana Carolina Laus
- Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil
| | - Luciane Sussuchi
- Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil
| | - Rui Manuel Reis
- Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil
| | - André Salim Khayat
- Oncology Research Center, Federal University of Pará, Belém, Brazil
- Institute of Biological Sciences, Federal University of Pará, Belém, Brazil
| | | | - Silma Regina Pereira
- Laboratory of Genetics and Molecular Biology, Department of Biology, Federal University of Maranhão, São Luís, Brazil
- *Correspondence: Silma Regina Pereira,
| |
Collapse
|
5
|
Gomes INF, da Silva-Oliveira RJ, da Silva LS, Martinho O, Evangelista AF, van Helvoort Lengert A, Leal LF, Silva VAO, dos Santos SP, Nascimento FC, Lopes Carvalho A, Reis RM. Comprehensive Molecular Landscape of Cetuximab Resistance in Head and Neck Cancer Cell Lines. Cells 2022; 11:154. [PMID: 35011716 PMCID: PMC8750399 DOI: 10.3390/cells11010154] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2021] [Revised: 12/17/2021] [Accepted: 12/31/2021] [Indexed: 12/15/2022] Open
Abstract
Cetuximab is the sole anti-EGFR monoclonal antibody that is FDA approved to treat head and neck squamous cell carcinoma (HNSCC). However, no predictive biomarkers of cetuximab response are known for HNSCC. Herein, we address the molecular mechanisms underlying cetuximab resistance in an in vitro model. We established a cetuximab resistant model (FaDu), using increased cetuximab concentrations for more than eight months. The resistance and parental cells were evaluated for cell viability and functional assays. Protein expression was analyzed by Western blot and human cell surface panel by lyoplate. The mutational profile and copy number alterations (CNA) were analyzed using whole-exome sequencing (WES) and the NanoString platform. FaDu resistant clones exhibited at least two-fold higher IC50 compared to the parental cell line. WES showed relevant mutations in several cancer-related genes, and the comparative mRNA expression analysis showed 36 differentially expressed genes associated with EGFR tyrosine kinase inhibitors resistance, RAS, MAPK, and mTOR signaling. Importantly, we observed that overexpression of KRAS, RhoA, and CD44 was associated with cetuximab resistance. Protein analysis revealed EGFR phosphorylation inhibition and mTOR increase in resistant cells. Moreover, the resistant cell line demonstrated an aggressive phenotype with a significant increase in adhesion, the number of colonies, and migration rates. Overall, we identified several molecular alterations in the cetuximab resistant cell line that may constitute novel biomarkers of cetuximab response such as mTOR and RhoA overexpression. These findings indicate new strategies to overcome anti-EGFR resistance in HNSCC.
Collapse
Affiliation(s)
- Izabela N. F. Gomes
- Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos 14784-400, Brazil; (I.N.F.G.); (R.J.d.S.-O.); (L.S.d.S.); (A.F.E.); (A.v.H.L.); (L.F.L.); (V.A.O.S.); (A.L.C.)
| | - Renato J. da Silva-Oliveira
- Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos 14784-400, Brazil; (I.N.F.G.); (R.J.d.S.-O.); (L.S.d.S.); (A.F.E.); (A.v.H.L.); (L.F.L.); (V.A.O.S.); (A.L.C.)
- Barretos School of Medicine Dr. Paulo Prata—FACISB, Barretos 14785-002, Brazil
| | - Luciane Sussuchi da Silva
- Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos 14784-400, Brazil; (I.N.F.G.); (R.J.d.S.-O.); (L.S.d.S.); (A.F.E.); (A.v.H.L.); (L.F.L.); (V.A.O.S.); (A.L.C.)
| | - Olga Martinho
- Life and Health Sciences Research Institute (ICVS), Medical School, University of Minho, 4710-057 Braga, Portugal; (O.M.); (F.C.N.)
| | - Adriane F. Evangelista
- Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos 14784-400, Brazil; (I.N.F.G.); (R.J.d.S.-O.); (L.S.d.S.); (A.F.E.); (A.v.H.L.); (L.F.L.); (V.A.O.S.); (A.L.C.)
| | - André van Helvoort Lengert
- Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos 14784-400, Brazil; (I.N.F.G.); (R.J.d.S.-O.); (L.S.d.S.); (A.F.E.); (A.v.H.L.); (L.F.L.); (V.A.O.S.); (A.L.C.)
| | - Letícia Ferro Leal
- Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos 14784-400, Brazil; (I.N.F.G.); (R.J.d.S.-O.); (L.S.d.S.); (A.F.E.); (A.v.H.L.); (L.F.L.); (V.A.O.S.); (A.L.C.)
- Barretos School of Medicine Dr. Paulo Prata—FACISB, Barretos 14785-002, Brazil
| | - Viviane Aline Oliveira Silva
- Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos 14784-400, Brazil; (I.N.F.G.); (R.J.d.S.-O.); (L.S.d.S.); (A.F.E.); (A.v.H.L.); (L.F.L.); (V.A.O.S.); (A.L.C.)
| | | | - Flávia Caroline Nascimento
- Life and Health Sciences Research Institute (ICVS), Medical School, University of Minho, 4710-057 Braga, Portugal; (O.M.); (F.C.N.)
| | - André Lopes Carvalho
- Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos 14784-400, Brazil; (I.N.F.G.); (R.J.d.S.-O.); (L.S.d.S.); (A.F.E.); (A.v.H.L.); (L.F.L.); (V.A.O.S.); (A.L.C.)
| | - Rui Manuel Reis
- Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos 14784-400, Brazil; (I.N.F.G.); (R.J.d.S.-O.); (L.S.d.S.); (A.F.E.); (A.v.H.L.); (L.F.L.); (V.A.O.S.); (A.L.C.)
- Life and Health Sciences Research Institute (ICVS), Medical School, University of Minho, 4710-057 Braga, Portugal; (O.M.); (F.C.N.)
- Laboratory of Molecular Diagnosis, Barretos Cancer Hospital, Barretos 14784-400, Brazil;
- 3ICVS/3B’s-PT Government Associate Laboratory, 4710-057 Braga, Portugal
| |
Collapse
|
6
|
Carobeli LR, Meirelles LEDF, Damke GMZF, Damke E, de Souza MVF, Mari NL, Mashiba KH, Shinobu-Mesquita CS, Souza RP, da Silva VRS, Gonçalves RS, Caetano W, Consolaro MEL. Phthalocyanine and Its Formulations: A Promising Photosensitizer for Cervical Cancer Phototherapy. Pharmaceutics 2021; 13:pharmaceutics13122057. [PMID: 34959339 PMCID: PMC8705941 DOI: 10.3390/pharmaceutics13122057] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2021] [Revised: 10/19/2021] [Accepted: 10/21/2021] [Indexed: 12/13/2022] Open
Abstract
Cervical cancer is one of the most common causes of cancer-related deaths in women worldwide. Despite advances in current therapies, women with advanced or recurrent disease present poor prognosis. Photodynamic therapy (PDT) has emerged as an effective therapeutic alternative to treat oncological diseases such as cervical cancer. Phthalocyanines (Pcs) are considered good photosensitizers (PS) for PDT, although most of them present high levels of aggregation and are lipophilic. Despite many investigations and encouraging results, Pcs have not been approved as PS for PDT of invasive cervical cancer yet. This review presents an overview on the pathophysiology of cervical cancer and summarizes the most recent developments on the physicochemical properties of Pcs and biological results obtained both in vitro in tumor-bearing mice and in clinical tests reported in the last five years. Current evidence indicates that Pcs have potential as pharmaceutical agents for anti-cervical cancer therapy. The authors firmly believe that Pc-based formulations could emerge as a privileged scaffold for the establishment of lead compounds for PDT against different types of cervical cancer.
Collapse
Affiliation(s)
- Lucimara R. Carobeli
- Department of Clinical Analysis and Biomedicine, Universidade Estadual de Maringá, Maringá 87020-900, PR, Brazil; (L.R.C.); (L.E.d.F.M.); (G.M.Z.F.D.); (E.D.); (M.V.F.d.S.); (N.L.M.); (K.H.M.); (C.S.S.-M.); (R.P.S.); (V.R.S.d.S.)
| | - Lyvia E. de F. Meirelles
- Department of Clinical Analysis and Biomedicine, Universidade Estadual de Maringá, Maringá 87020-900, PR, Brazil; (L.R.C.); (L.E.d.F.M.); (G.M.Z.F.D.); (E.D.); (M.V.F.d.S.); (N.L.M.); (K.H.M.); (C.S.S.-M.); (R.P.S.); (V.R.S.d.S.)
| | - Gabrielle M. Z. F. Damke
- Department of Clinical Analysis and Biomedicine, Universidade Estadual de Maringá, Maringá 87020-900, PR, Brazil; (L.R.C.); (L.E.d.F.M.); (G.M.Z.F.D.); (E.D.); (M.V.F.d.S.); (N.L.M.); (K.H.M.); (C.S.S.-M.); (R.P.S.); (V.R.S.d.S.)
| | - Edilson Damke
- Department of Clinical Analysis and Biomedicine, Universidade Estadual de Maringá, Maringá 87020-900, PR, Brazil; (L.R.C.); (L.E.d.F.M.); (G.M.Z.F.D.); (E.D.); (M.V.F.d.S.); (N.L.M.); (K.H.M.); (C.S.S.-M.); (R.P.S.); (V.R.S.d.S.)
| | - Maria V. F. de Souza
- Department of Clinical Analysis and Biomedicine, Universidade Estadual de Maringá, Maringá 87020-900, PR, Brazil; (L.R.C.); (L.E.d.F.M.); (G.M.Z.F.D.); (E.D.); (M.V.F.d.S.); (N.L.M.); (K.H.M.); (C.S.S.-M.); (R.P.S.); (V.R.S.d.S.)
| | - Natália L. Mari
- Department of Clinical Analysis and Biomedicine, Universidade Estadual de Maringá, Maringá 87020-900, PR, Brazil; (L.R.C.); (L.E.d.F.M.); (G.M.Z.F.D.); (E.D.); (M.V.F.d.S.); (N.L.M.); (K.H.M.); (C.S.S.-M.); (R.P.S.); (V.R.S.d.S.)
| | - Kayane H. Mashiba
- Department of Clinical Analysis and Biomedicine, Universidade Estadual de Maringá, Maringá 87020-900, PR, Brazil; (L.R.C.); (L.E.d.F.M.); (G.M.Z.F.D.); (E.D.); (M.V.F.d.S.); (N.L.M.); (K.H.M.); (C.S.S.-M.); (R.P.S.); (V.R.S.d.S.)
| | - Cristiane S. Shinobu-Mesquita
- Department of Clinical Analysis and Biomedicine, Universidade Estadual de Maringá, Maringá 87020-900, PR, Brazil; (L.R.C.); (L.E.d.F.M.); (G.M.Z.F.D.); (E.D.); (M.V.F.d.S.); (N.L.M.); (K.H.M.); (C.S.S.-M.); (R.P.S.); (V.R.S.d.S.)
| | - Raquel P. Souza
- Department of Clinical Analysis and Biomedicine, Universidade Estadual de Maringá, Maringá 87020-900, PR, Brazil; (L.R.C.); (L.E.d.F.M.); (G.M.Z.F.D.); (E.D.); (M.V.F.d.S.); (N.L.M.); (K.H.M.); (C.S.S.-M.); (R.P.S.); (V.R.S.d.S.)
| | - Vânia R. S. da Silva
- Department of Clinical Analysis and Biomedicine, Universidade Estadual de Maringá, Maringá 87020-900, PR, Brazil; (L.R.C.); (L.E.d.F.M.); (G.M.Z.F.D.); (E.D.); (M.V.F.d.S.); (N.L.M.); (K.H.M.); (C.S.S.-M.); (R.P.S.); (V.R.S.d.S.)
| | - Renato S. Gonçalves
- Department of Chemistry, Universidade Estadual de Maringá, Maringá 87020-900, PR, Brazil; (R.S.G.); (W.C.)
| | - Wilker Caetano
- Department of Chemistry, Universidade Estadual de Maringá, Maringá 87020-900, PR, Brazil; (R.S.G.); (W.C.)
| | - Márcia E. L. Consolaro
- Department of Clinical Analysis and Biomedicine, Universidade Estadual de Maringá, Maringá 87020-900, PR, Brazil; (L.R.C.); (L.E.d.F.M.); (G.M.Z.F.D.); (E.D.); (M.V.F.d.S.); (N.L.M.); (K.H.M.); (C.S.S.-M.); (R.P.S.); (V.R.S.d.S.)
- Correspondence: ; Tel.: +55-44-3011-5455
| |
Collapse
|
7
|
de Andrade DAP, da Silva LS, Laus AC, de Lima MA, Berardinelli GN, da Silva VD, Matsushita GDM, Bonatelli M, da Silva ALV, Evangelista AF, Carvalho JP, Reis RM, Dos Reis R. A 4-Gene Signature Associated With Recurrence in Low- and Intermediate-Risk Endometrial Cancer. Front Oncol 2021; 11:729219. [PMID: 34485158 PMCID: PMC8416164 DOI: 10.3389/fonc.2021.729219] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2021] [Accepted: 07/30/2021] [Indexed: 12/28/2022] Open
Abstract
Background The molecular profile of endometrial cancer has become an important tool in determining patient prognosis and their optimal adjuvant treatment. In addition to The Cancer Genome Atlas (TCGA), simpler tools have been developed, such as the Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE). We attempted to determine a genetic signature to build a recurrence risk score in patients diagnosed with low- and intermediate-risk endometrial cancer. Methods A case-control study was conducted. The eligible patients were women diagnosed with recurrence low- and intermediate-risk endometrial cancer between January 2009 and December 2014 at a single institution; the recurrence patients were matched to two nonrecurrence patients with the same diagnosis by age and surgical staging. Following RNA isolation of 51 cases, 17 recurrence and 34 nonrecurrence patients, the expression profile was determined using the nCounter® PanCancer Pathways Panel, which contains 770 genes. Results The expression profile was successfully characterized in 49/51 (96.1%) cases. We identified 12 genes differentially expressed between the recurrence and nonrecurrence groups. The ROC curve for each gene was generated, and all had AUCs higher than 0.7. After backward stepwise logistic regression, four genes were highlighted: FN1, DUSP4, LEF1, and SMAD9. The recurrence risk score was calculated, leading to a ROC curve of the 4-gene model with an AUC of 0.93, sensitivity of 100%, and specificity of 72.7%. Conclusion We identified a four-gene signature that may be associated with recurrence in patients with low- and intermediate-risk endometrial cancer. This finding suggests a new prognostic factor in this poorly explored group of patients with endometrial cancer.
Collapse
Affiliation(s)
- Diocésio Alves Pinto de Andrade
- InORP ONCOCLÍNICAS Group, Oncology Institute of Ribeirão Preto, Ribeirão Preto, Brazil.,Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil
| | | | - Ana Carolina Laus
- Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil
| | - Marcos Alves de Lima
- Epidemiology and Biostatistics Nucleus, Barretos Cancer Hospital, Barretos, Brazil
| | | | | | | | - Murilo Bonatelli
- Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil
| | | | | | - Jesus Paula Carvalho
- Discipline of Gynecology, Instituto do Cancer do Estado de São Paulo (ICESP), Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
| | - Rui Manuel Reis
- Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil.,Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal.,ICVS/3B's - PT Government Associate Laboratory, Braga/Guimarães, Portugal
| | - Ricardo Dos Reis
- Department of Gynecologic Oncology, Barretos Cancer Hospital, Barretos, Brazil
| |
Collapse
|
8
|
Chen M, Liang X, Liang Z, Zhao L. Study on the effect and mechanism of NFKBIA on cervical cancer progress in vitro and in vivo. J Obstet Gynaecol Res 2021; 47:3931-3942. [PMID: 34342105 DOI: 10.1111/jog.14947] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2020] [Revised: 05/31/2021] [Accepted: 07/07/2021] [Indexed: 11/30/2022]
Abstract
AIM NFKBIA is frequently encountered. However, its expression and relevance of the proliferation, invasion, and migration in human cervical cancer (CC) remain unclear. The role and novel mechanism of NFKBIA in CC progression were investigated in this study. METHODS We analyzed the expression of NFKBIA in CC and adjacent normal tissues and explored the proliferation, migration, and invasion of HeLa cells by treating with either wild-type NFKBIA plasmid or NFKBIA siRNA. Effect of NFKBIA on the epithelial-mesenchymal transition (EMT) and the β-catenin-mediated transcription of target genes were evaluated subsequently. RESULTS NFKBIA expression was lower in CC tissues than that of adjacent tissues. An obvious dysregulation of NFKBIA overexpression was revealed in CC cell proliferation, invasion, and migration, which differed from the effect of knockdown NFKBIA. NFKBIA overexpression facilitated the expression of both phosphorylated β-catenin and E-cadherin protein. It inhibited the expression of vimentin, TWIST, as well as downstream targets of β-catenin including c-MYC, TCF-4 and MMP14. Conversely, NFKBIA silencing elevated the expression of c-MYC, TCF-4, and MMP14, and promoted the EMT in HeLa cells. Both endogenous and exogenous NFKBIA interacted with β-catenin. Moreover, β-catenin overexpression stemmed effects of NFKBIA on the proliferation, migration, and invasion of HeLa cells. By overexpressing NFKBIA in vivo, the volume and size of tumors were notably decreased, while no obvious alteration was found in mice body weight. CONCLUSION By inhibiting β-catenin-mediated transcription, NFKBIA functioning as a tumor suppressor might be introduced as a novel anti-metastatic agent for the treatment of targeted CC.
Collapse
Affiliation(s)
- Mengyue Chen
- Department of Gynaecology, The First People's Hospital of Chongqing Liang Jiang New Area, Chongqing, China
| | - Xiaolong Liang
- Department of Obstetrics & Gynaecology, Southwest Hospital, Army Medical University, Chongqing, China
| | - Zhiqing Liang
- Department of Obstetrics & Gynaecology, Southwest Hospital, Army Medical University, Chongqing, China
| | - Limei Zhao
- Department of Gynaecology, The First People's Hospital of Chongqing Liang Jiang New Area, Chongqing, China
| |
Collapse
|
9
|
Causin RL, de Freitas AJA, Trovo Hidalgo Filho CM, dos Reis R, Reis RM, Marques MMC. A Systematic Review of MicroRNAs Involved in Cervical Cancer Progression. Cells 2021; 10:668. [PMID: 33803022 PMCID: PMC8002658 DOI: 10.3390/cells10030668] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2021] [Revised: 03/02/2021] [Accepted: 03/10/2021] [Indexed: 12/16/2022] Open
Abstract
To obtain a better understanding on the role of microRNAs in the progression of cervical cancer, a systematic review was performed to analyze cervical cancer microRNA studies. We provide an overview of the studies investigating microRNA expression in relation to cervical cancer (CC) progression, highlighting their common outcomes and target gene interactions according to the regulatory pathways. To achieve this, we systematically searched through PubMed MEDLINE, EMBASE, and Google Scholar for all articles between April 2010 and April 2020, in accordance with the PICO acronym (participants, interventions, comparisons, outcomes). From 27 published reports, totaling 1721 cases and 1361 noncancerous control tissue samples, 26 differentially expressed microRNAs (DEmiRNAs) were identified in different International Federation of Gynecology and Obstetrics (FIGO) stages of cervical cancer development. It was identified that some of the dysregulated microRNAs were associated with specific stages of cervical cancer development. The results indicated that DEmiRNAs in different stages of cervical cancer were functionally involved in several key hallmarks of cancer, such as evading growth suppressors, enabling replicative immortality, activation of invasion and metastasis, resisting cell death, and sustained proliferative signaling. These dysregulated microRNAs could play an important role in cervical cancer's development. Some of the stage-specific microRNAs can also be used as biomarkers for cancer classification and monitoring the progression of cervical cancer.
Collapse
Affiliation(s)
- Rhafaela Lima Causin
- Molecular Oncology Research Center, Barretos Cancer Hospital, Teaching and Research Institute, Barretos-SP 14784-400, Brazil; (R.L.C.); (A.J.A.d.F.); (R.M.R.)
| | - Ana Julia Aguiar de Freitas
- Molecular Oncology Research Center, Barretos Cancer Hospital, Teaching and Research Institute, Barretos-SP 14784-400, Brazil; (R.L.C.); (A.J.A.d.F.); (R.M.R.)
| | | | - Ricardo dos Reis
- Gynecologic Oncology Department, Barretos Cancer Hospital, Barretos, São Paulo 14784-400, Brazil;
| | - Rui Manuel Reis
- Molecular Oncology Research Center, Barretos Cancer Hospital, Teaching and Research Institute, Barretos-SP 14784-400, Brazil; (R.L.C.); (A.J.A.d.F.); (R.M.R.)
- Life and Health Sciences Research Institute (ICVS), Medical School, University of Minho, 4704-553 Braga, Portugal
- ICVS/3B’s-PT Government Associate Laboratory, 4806-909 Braga/Guimarães, Portugal
| | - Márcia Maria Chiquitelli Marques
- Molecular Oncology Research Center, Barretos Cancer Hospital, Teaching and Research Institute, Barretos-SP 14784-400, Brazil; (R.L.C.); (A.J.A.d.F.); (R.M.R.)
- Barretos School of Health Sciences, Dr. Paulo Prata–FACISB, Barretos, São Paulo 14785-002, Brazil
| |
Collapse
|
10
|
Skok K, Gradišnik L, Maver U, Kozar N, Sobočan M, Takač I, Arko D, Kavalar R. Gynaecological cancers and their cell lines. J Cell Mol Med 2021; 25:3680-3698. [PMID: 33650759 PMCID: PMC8051715 DOI: 10.1111/jcmm.16397] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2021] [Revised: 02/08/2021] [Accepted: 02/10/2021] [Indexed: 12/24/2022] Open
Abstract
Cell lines are widely used for various research purposes including cancer and drug research. Recently, there have been studies that pointed to discrepancies in the literature and usage of cell lines. That is why we have prepared a comprehensive overview of the most common gynaecological cancer cell lines, their literature, a list of currently available cell lines, and new findings compared with the original studies. A literature review was conducted via MEDLINE, PubMed and ScienceDirect for reviews in the last 5 years to identify research and other studies related to gynaecological cancer cell lines. We present an overview of the current literature with reference to the original studies and pointed to certain inconsistencies in the literature. The adherence to culturing rulesets and the international guidelines helps in minimizing replication failure between institutions. Evidence from the latest research suggests that despite certain drawbacks, variations of cancer cell lines can also be useful in regard to a more diverse genomic landscape.
Collapse
Affiliation(s)
- Kristijan Skok
- Department of pathology, General Hospital Graz II, Graz, Austria.,Institute of Biomedical Sciences, Faculty of Medicine, University of Maribor, Maribor, Slovenia
| | - Lidija Gradišnik
- Institute of Biomedical Sciences, Faculty of Medicine, University of Maribor, Maribor, Slovenia
| | - Uroš Maver
- Institute of Biomedical Sciences, Faculty of Medicine, University of Maribor, Maribor, Slovenia
| | - Nejc Kozar
- Division of Gynecology and Perinatology, University Medical Center Maribor, Maribor, Slovenia.,Faculty of Medicine, University of Maribor, Maribor, Slovenia
| | - Monika Sobočan
- Division of Gynecology and Perinatology, University Medical Center Maribor, Maribor, Slovenia.,Faculty of Medicine, University of Maribor, Maribor, Slovenia
| | - Iztok Takač
- Division of Gynecology and Perinatology, University Medical Center Maribor, Maribor, Slovenia.,Faculty of Medicine, University of Maribor, Maribor, Slovenia
| | - Darja Arko
- Division of Gynecology and Perinatology, University Medical Center Maribor, Maribor, Slovenia.,Faculty of Medicine, University of Maribor, Maribor, Slovenia
| | - Rajko Kavalar
- Faculty of Medicine, University of Maribor, Maribor, Slovenia.,Department of Pathology, University Medical Center Maribor, Maribor, Slovenia
| |
Collapse
|
11
|
Adeyemi JO, Onwudiwe DC, Nundkumar N, Singh M. Diorganotin(iv) benzyldithiocarbamate complexes: synthesis, characterization, and thermal and cytotoxicity study. OPEN CHEM 2020. [DOI: 10.1515/chem-2020-0037] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
AbstractAmmonium benzyldithiocarbamate, represented as NH4L, was prepared and used in the complexation reaction involving three organotin(iv) salts, represented as R2SnCl2 (R = CH3, C4H9, and C6H5). The structures of the synthesized complexes [(CH3)2SnL2] (1), [(C4H9)2SnL2] (2), and [(C6H5)2SnL2] (3) were established using various spectroscopic techniques (Fourier transform infrared spectroscopy, 1H NMR, 13C NMR, and 119Sn NMR) and elemental analysis. Thermal decomposition of the complexes using thermogravimetric analysis under nitrogen showed no definite pathway in the pattern of the complexes even though they are structurally related. X-ray diffraction studies of the final residue showed a common diffraction pattern for the complexes and confirmed SnS as the product of the thermal treatment. Cytotoxicity studies of these complexes against the human tumor cell lines (HeLa and MCF-7) compared favorably with the used standard 5-fluorouracil drug, with complexes 2 and 3 showing very good activity toward the used cell lines.
Collapse
Affiliation(s)
- Jerry O. Adeyemi
- Material Science Innovation and Modeling (MaSIM) Research Focus Area, Faculty of Natural and Agricultural Science, North-West University (Mafikeng Campus), Private Bag X2046, Mmabatho, South Africa
- Department of Chemistry, Faculty of Natural and Agricultural Science, North-West University (Mafikeng Campus), Private Bag X2046, Mmabatho 2735, South Africa
| | - Damian C. Onwudiwe
- Material Science Innovation and Modeling (MaSIM) Research Focus Area, Faculty of Natural and Agricultural Science, North-West University (Mafikeng Campus), Private Bag X2046, Mmabatho, South Africa
- Department of Chemistry, Faculty of Natural and Agricultural Science, North-West University (Mafikeng Campus), Private Bag X2046, Mmabatho 2735, South Africa
| | - Nirasha Nundkumar
- Nano-Gene and Drug Delivery Laboratory, Department of Biochemistry, University of KwaZulu-Natal, Private Bag X54001, Durban 4000, South Africa
| | - Moganavelli Singh
- Nano-Gene and Drug Delivery Laboratory, Department of Biochemistry, University of KwaZulu-Natal, Private Bag X54001, Durban 4000, South Africa
| |
Collapse
|
12
|
Zhang L, Li H, Yuan M, Li M, Zhang S. Cervical Cancer Cells-Secreted Exosomal microRNA-221-3p Promotes Invasion, Migration and Angiogenesis of Microvascular Endothelial Cells in Cervical Cancer by Down-Regulating MAPK10 Expression. Cancer Manag Res 2019; 11:10307-10319. [PMID: 31849520 PMCID: PMC6910095 DOI: 10.2147/cmar.s221527] [Citation(s) in RCA: 40] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2019] [Accepted: 11/04/2019] [Indexed: 12/12/2022] Open
Abstract
Purpose Cervical cancer (CC) is recognized as a common cancer with a high risk worldwide. Exosomal microRNAs (miRNAs) have received attention for their increasing potentials in CC therapy. In this study, we identify the involvement of miR-221-3p in CC progression by affecting angiogenesis of microvascular endothelial cells (MVECs). Methods Microarray-based gene expression profiling was conducted to retrieve the differentially expressed genes in CC. The expression patterns of miR-221-3p were measured by RT-qPCR, while Western blot analysis and RT-qPCR were performed to determine the expression of MAPK10 in the CC tissues and cells, followed by verification of the interaction between miR-221-3p and MAPK10 using dual luciferase reporter gene assay. Then the effects of miR-221-3p and MAPK10 on cell activities were assessed through gain- and loss-of-function experiments in CC. Subsequently, the impact of exosomal miR-221-3p on MVEC proliferation, migration, invasion and angiogenesis was examined after exosomal isolation from CC cells and co-cultured with MVECs. Results Gene expression profile showed that MAPK10 might participate in CC with a low expression. Moreover, miR-221-3p was highly expressed and MAPK10 was poorly expressed in CC tissues and cells. It was observed that miR-221-3p targeted MAPK10. Depletion of miR-221-3p blocked the cell proliferation, invasion and migration in CC by up-regulating MAPK10. Moreover, CC cells-derived exosomes carrying miR-221-3p accelerated MVEC proliferation, invasion, migration and angiogenesis in CC by regulating MAPK10. Conclusion CC cells-derived exosomes harboring miR-221-3p enhanced MVEC angiogenesis in CC by decreasing MAPK10.
Collapse
Affiliation(s)
- Lu Zhang
- Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan 250012, People's Republic of China
| | - Huihui Li
- Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan 250012, People's Republic of China
| | - Ming Yuan
- Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan 250012, People's Republic of China
| | - Mingbao Li
- Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan 250012, People's Republic of China
| | - Shuquan Zhang
- Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan 250012, People's Republic of China
| |
Collapse
|